Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Consolidated Water Co. Ltd.CWCO · Entity 5519 | Director | December 15, 2025 | December 16, 2025 |
| RYTHM, Inc.AGFY · Entity 2092 | Director | April 24, 2024 | April 26, 2024 |
| SKYX Platforms Corp.SKYX · Entity 6432 | Director · Chief Executive Officer | September 12, 2026 | September 14, 2026 |
| Vivos Therapeutics, Inc.VVOS · Entity 8396 | Director | June 20, 2024 | June 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Consolidated Water Co. Ltd.
Report date December 15, 2025 · Filed December 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,527 |
Reported balance
After 2025-12-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-15 · Grant · Acquired 1,979 · Balance 38,527 F1: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F2: Includes 5 shares acquired under the Company's dividend reinvestment plan that have not previously been included in the Reporting Person's beneficial holdings. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year.
F2: Includes 5 shares acquired under the Company's dividend reinvestment plan that have not previously been included in the Reporting Person's beneficial holdings.
RYTHM, Inc.
Report date April 24, 2024 · Filed April 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 54,091 |
Reported balance
After 2024-04-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-24 · Grant · Acquired 54,091 · Balance 54,091 F1: Grant of restricted stock units under the Agrify Corporation 2022 Omnibus Equity Incentive Plan (the "Plan"). The restricted stock units were granted in lieu of cash compensation that would otherwise be owed to the reporting person. F2: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the issuer. F3: 100% of the restricted stock unit will vest on April 24, 2025, subject to obtaining shareholder approval for an increase in shares available under the Plan sufficient to grant the units, and subject to the reporting person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units under the Agrify Corporation 2022 Omnibus Equity Incentive Plan (the "Plan"). The restricted stock units were granted in lieu of cash compensation that would otherwise be owed to the reporting person.
F2: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the issuer.
F3: 100% of the restricted stock unit will vest on April 24, 2025, subject to obtaining shareholder approval for an increase in shares available under the Plan sufficient to grant the units, and subject to the reporting person's continuous service through such vesting date.
SKYX Platforms Corp.
Report date September 12, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 931,149 |
Reported balance
After 2026-09-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-12 · Tax withholding · Disposed 19,673 · Balance 931,149 F9: The reporting person has elected to satisfy his tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") by directing the issuer to withhold shares otherwise issuable upon vesting of the grants. F10: Includes 167,500 RSUs, which will vest as follows, subject to continued employment through the vesting date: (i) 30,000 RSUs, which will vest on March 12, 2027; (ii) 100,000 RSUs, which will vest in two equal annual installments beginning on January 1, 2027; and (iii) 37,500 RSUs, which will vest in three equal annual installments beginning on June 1, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2027-04-19 | Direct | 150,000 |
Reported balance
Holding disclosure · report date 2026-09-12 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 150,000 F3: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2027-04-19 | Direct | 150,000 |
Reported balance
Holding disclosure · report date 2026-09-12 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 150,000 F3: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2026-12-31 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2026-09-12 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 100,000 F3: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.34 · Expires 2027-03-11 | Direct | 17,500 |
Reported balance
Holding disclosure · report date 2026-09-12 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 17,500 F3: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28 · Expires 2028-04-05 | Direct | 17,500 |
Reported balance
Holding disclosure · report date 2026-09-12 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 17,500 F3: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2028-09-12 | Direct | 450,000 |
Reported balance
Holding disclosure · report date 2026-09-12 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 450,000 F4: Options vest over 3.5 years as follows, subject to continued employment through the vesting date: 120,000 vested on September 12, 2023; 300,000 vest in six semi-annual installments of 50,000, beginning on March 12, 2024; and 30,000 vest on March 12, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2030-03-27 | Direct | 150,000 |
Reported balance
Holding disclosure · report date 2026-09-12 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 150,000 F5: Options vest in three equal annual installments, beginning on March 27, 2025, the grant date, subject to continued employment through the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.15 · Expires 2030-12-15 | Direct | 150,000 |
Reported balance
Holding disclosure · report date 2026-09-12 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 150,000 F6: Options vest in three equal annual installments, beginning on January 1, 2026, subject to continued employment through the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2031-06-14 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2026-09-12 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 50,000 F7: Options vest in four equal installments of 12,500 on June 14, 2026, June 1, 2027, June 1, 2028 and June 1, 2029, subject to continued employment through the vesting date. |
| Subordinated Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2025-05-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-12 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance Not disclosed F1: The principal amount, plus any accrued and unpaid interest, is convertible into shares of common stock at the holder's discretion at the conversion price of $3.00 per share. F2: Represents the principal amount of the convertible note and excludes interest that may accrue. Beginning January 1, 2024, the note accrues interest at a rate of 10.0% per annum, which is payable annually, in cash or common stock, at the holder's discretion. Prior to such date, the note accrued interest at a rate of 6.0% per annum. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2026-09-12 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 10,000 F8: The Series A-1 Preferred Stock (the "Preferred Stock") has an original issue price of $25.00 per share and is convertible at any time, at the holder's option, into shares of the issuer's common stock at an adjusted conversion price of $1.20 per share (or approximately 20.83 shares of common stock for each share of Preferred Stock). Until October 4, 2026, the Preferred Stock is subject to mandatory conversion by the issuer upon the occurrence of certain specified events. In addition, the issuer may redeem the Preferred Stock for cash upon the occurrence of certain events or at any time beginning October 4, 2027. The Preferred Stock has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The principal amount, plus any accrued and unpaid interest, is convertible into shares of common stock at the holder's discretion at the conversion price of $3.00 per share.
F2: Represents the principal amount of the convertible note and excludes interest that may accrue. Beginning January 1, 2024, the note accrues interest at a rate of 10.0% per annum, which is payable annually, in cash or common stock, at the holder's discretion. Prior to such date, the note accrued interest at a rate of 6.0% per annum.
F3: Fully exercisable.
F4: Options vest over 3.5 years as follows, subject to continued employment through the vesting date: 120,000 vested on September 12, 2023; 300,000 vest in six semi-annual installments of 50,000, beginning on March 12, 2024; and 30,000 vest on March 12, 2027.
F5: Options vest in three equal annual installments, beginning on March 27, 2025, the grant date, subject to continued employment through the vesting date.
F6: Options vest in three equal annual installments, beginning on January 1, 2026, subject to continued employment through the vesting date.
F7: Options vest in four equal installments of 12,500 on June 14, 2026, June 1, 2027, June 1, 2028 and June 1, 2029, subject to continued employment through the vesting date.
F8: The Series A-1 Preferred Stock (the "Preferred Stock") has an original issue price of $25.00 per share and is convertible at any time, at the holder's option, into shares of the issuer's common stock at an adjusted conversion price of $1.20 per share (or approximately 20.83 shares of common stock for each share of Preferred Stock). Until October 4, 2026, the Preferred Stock is subject to mandatory conversion by the issuer upon the occurrence of certain specified events. In addition, the issuer may redeem the Preferred Stock for cash upon the occurrence of certain events or at any time beginning October 4, 2027. The Preferred Stock has no expiration date.
F9: The reporting person has elected to satisfy his tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") by directing the issuer to withhold shares otherwise issuable upon vesting of the grants.
F10: Includes 167,500 RSUs, which will vest as follows, subject to continued employment through the vesting date: (i) 30,000 RSUs, which will vest on March 12, 2027; (ii) 100,000 RSUs, which will vest in two equal annual installments beginning on January 1, 2027; and (iii) 37,500 RSUs, which will vest in three equal annual installments beginning on June 1, 2027.
Vivos Therapeutics, Inc.
Report date June 20, 2024 · Filed June 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2029-06-20 | Direct | 7,467 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 4,000 · Balance 7,467 F1: On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2021 Filed Jan 3, 2022 11:52 UTC | RYTHM, Inc. AGFY · Entity 2092 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001213900-22-000035 · ownership.xml · derivative · entry 1 SOKOLOW LEONARD J · CIK 0000923890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-31 F1 · derivative.exercise_date: The Reporting Person received an option to purchase Common Stock from the Issuer pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan. The option will vest in 36 equal monthly installments beginning on January 1, 2022. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:44 UTC | Consolidated Water Co. Ltd. CWCO · Entity 5519 | GrantCommon Stock | 4,070 | $10.32 | $42,002.40 |
DisclosureSEC source: 0001415889-21-005520 · form4-11242021_011130.xml · nonDerivative · entry 1 SOKOLOW LEONARD J · CIK 0000923890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,904 F1 · shares: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F1 · price: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F2 · balance_after: Includes 7 shares acquired under the Company's dividend reinvestment plan that have not previously been included in the Reporting Person's beneficial holdings. Read SEC document |
| August 05, 2021 Filed Aug 11, 2021 01:41 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $2.72 Strike: $2.72 | $81,600.00 |
DisclosureSEC source: 0001493152-21-019246 · ownership.xml · derivative · entry 1 SOKOLOW LEONARD J · CIK 0000923890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,667 Underlying: Common Stock · 46,667 shares Expires 2026-08-05 F1 · derivative.exercise_date: 30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 22:00 UTC | Consolidated Water Co. Ltd. CWCO · Entity 5519 | GrantCommon Stock | 2,585 | $16.25 | $42,006.25 |
DisclosureSEC source: 0001415889-20-002944 · form4-12162020_051239.xml · nonDerivative · entry 1 SOKOLOW LEONARD J · CIK 0000923890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,827 F1 · shares: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F1 · price: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F2 · balance_after: Includes 6 shares acquired under the Company's dividend reinvestment plan that have not previously been included in the Reporting Person's beneficial holdings. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 21:16 UTC | Consolidated Water Co. Ltd. CWCO · Entity 5519 | GrantCOMMON STOCK | 2,913 | $13.73 | $39,995.49 |
DisclosureSEC source: 0001104659-19-070602 · tm1923836-7_4.xml · nonDerivative · entry 1 SOKOLOW LEONARD J · CIK 0000923890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,236 F1 · shares: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F1 · price: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F2 · balance_after: Includes 6 shares acquired under the Company's dividend reinvestment plan that have not previously been included in the Reporting Person's beneficial holdings. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 21:07 UTC | Consolidated Water Co. Ltd. CWCO · Entity 5519 | GrantCOMMON STOCK | 2,657 | $12.80 | $34,009.60 |
DisclosureSEC source: 0001144204-18-064280 · tv508573_form4.xml · nonDerivative · entry 1 SOKOLOW LEONARD J · CIK 0000923890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,317 F1 · shares: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F1 · price: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F2 · balance_after: Includes 6 shares acquired under the Company's dividend reinvestment plan that have not previously been included in the Reporting Person's beneficial holdings. Read SEC document |
| November 20, 2017 Filed Nov 20, 2017 21:15 UTC | Consolidated Water Co. Ltd. CWCO · Entity 5519 | GrantCOMMON STOCK | 2,487 | $11.62 | $28,898.94 |
DisclosureSEC source: 0001144204-17-060163 · tv479381_4.xml · nonDerivative · entry 1 SOKOLOW LEONARD J · CIK 0000923890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,654 F1 · shares: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F1 · price: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F2 · balance_after: Includes 6 shares acquired under the Company's dividend reinvestment plan that have not previously been included in the Reporting Person's beneficial holdings. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 02:41 UTC | Consolidated Water Co. Ltd. CWCO · Entity 5519 | GrantCOMMON STOCK | 2,368 | $11.32 | $26,805.76 |
DisclosureSEC source: 0001144204-16-140388 · v455166_4.xml · nonDerivative · entry 1 SOKOLOW LEONARD J · CIK 0000923890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,161 F1 · shares: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F1 · price: Shares granted under the Company's non-executive directors share grant plan. The number of shares issued is calculated by dividing the accumulated share attendance fees by the prevailing market price on October 1st of the preceding year. F2 · balance_after: Includes 4 shares acquired under the Company's dividend reinvestment plan that have not previously been included in the Reporting Person's beneficial holdings. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.